Codexis signs agreement with siRNA drug developer to explore ECO Synthesis platform

• Codexis signed an agreement with an unnamed siRNA drug developer to evaluate its ECO Synthesis platform for stereo-defined siRNA fragments.
• Work includes enzymatic production of stereo-defined oligonucleotide fragments for duplex assembly via ligation, a potential alternative to solid-phase synthesis.
• The parties will compare enzymatic fragments with solid-phase oligonucleotide synthesis on purity, product quality, and ligation performance for potential clinical use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280600PRIMZONEFULLFEED9834773) on September 28, 2026, and is solely responsible for the information contained therein.